Evrizam (piracetam, Cinnarizine) capsules 400 mg/25 mg. №60


Manufacturer: Ukraine

Disorders of cerebral circulation Supportive treatment for symptoms of cerebrovascular origin, which include memory and thinking disorders, decreased concentration, mood disorders (irritability). Migraine prevention. Imbalance Supportive treatment for symptoms of labyrinth disorders that include fainting, tinnitus, nystagmus, nausea, and vomiting. Motion sickness Prevention of motion sickness.



Evrizam Storage
active substances: piracetam, cinnarizine;

1 capsule contains: piracetam – 400 mg, cinnarizine in terms of 100% dry matter – 25 mg;

excipients: lactose monohydrate, colloidal anhydrous silica, magnesium stearate;

capsule composition: gelatin, iron oxide yellow (E 172), iron oxide red (E 172), titanium dioxide (E 171).

Evrizam Dosage form

Main physical and chemical properties: hard gelatin capsules № 0. The body of the capsule is white and the lid is beige. Capsule contents – a crystalline powder mixture of white or almost white color.

Pharmacotherapeutic group
Psychostimulants and nootropic drugs.

ATX code N06B X.

Pharmacological properties


Euryzam – a combined drug. The active components of the drug are piracetam, a cyclic derivative of γ-aminobutyric acid, and cinnarizine – a selective antagonist of calcium channels.

Piracetam is a nootropic drug that acts on the brain, improving cognitive functions such as learning ability, memory, attention, and mental performance. The mechanisms of the drug’s effect on the central nervous system (CNS) are probably several: changes in the rate of propagation of excitation in the brain; enhancement of metabolic processes in nerve cells; improving microcirculation by affecting the rheological characteristics of the blood, but without vasodilating action. Euryzam improves connections between the hemispheres of the brain and synaptic conduction in neocortical structures. After long-term use of the drug in patients with decreased brain function there is an improvement in cognitive function, improved attention.

Cinnarizine inhibits the contraction of vascular smooth muscle cells by blocking calcium channels. In addition to direct calcium antagonism, cinnarizine reduces the contractile action of vasoactive substances, such as norepinephrine and serotonin, by blocking their controlled calcium channel receptors. Blockade of calcium intake to cells depends on the type of tissue, the result of which is anti-vasoconstrictor action without affecting blood pressure and heart rate. Cinnarizine may further improve insufficient microcirculation by increasing the elasticity of the erythrocyte membrane and reducing blood viscosity. Increases cellular resistance to hypoxia. Cinnarizine inhibits the stimulation of the vestibular system, which results in the suppression of nystagmus and other autonomic disorders. Cinnarizine prevents acute dizziness.

Evrizam Pharmacokinetics.

The drug is rapidly and completely absorbed in the gastrointestinal tract. Cinnarizine reaches peak plasma concentrations one hour after oral administration. Completely metabolized. It is 91% bound to blood proteins. 60% is excreted unchanged in the feces, residual amounts – in the urine in the form of metabolites.

The maximum plasma concentration of piracetam is reached in 2-6 hours. Piracetam freely penetrates the blood-brain barrier and is excreted unchanged in the urine.

Chronic and latent cerebral insufficiency in atherosclerosis and hypertension; angiodystonic ischemic stroke and the condition after a stroke.
Posttraumatic cerebrastenia.
Encephalopathy of various origins.
Psychoorganic syndrome with a predominance of memory impairment and other cognitive functions.
Labyrinopathy – dizziness, tinnitus, nausea, vomiting, nystagmus.
Meniere’s syndrome.
Prevention of kinetosis.

Hypersensitivity to piracetam, cinnarizine or to any of the excipients; individual sensitivity to pyrrolidone derivatives.

Severe renal failure, acute cerebrovascular accident (hemorrhagic stroke), Huntington’s chorea, parkinsonism, increased intraocular pressure, psychomotor agitation.

Pregnancy or breastfeeding.